Drug intelligence / Profile preview

dicycloverine + simethicone

Development stage
Unknown
Lead developer
Howards Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Pedgrib is a pediatric combination medication developed by Howards Pharma, primarily indicated for the treatment of infantile colic and gastrointestinal spasms. It consists of two small molecule active ingredients: dicycloverine (also known as dicyclomine) and simethicone. Dicycloverine functions as an antispasmodic by antagonizing muscarinic acetylcholine receptors on gastrointestinal smooth muscle, thereby reducing contractions and pain. Simethicone acts as an anti-foaming agent that decreases the surface tension of gas bubbles in the digestive tract, facilitating their coalescence and expulsion. This dual-action approach addresses both the muscular spasms and the gas accumulation associated with pediatric abdominal distress. The product is approved and marketed as an oral solution or drops.

Brand names
Pedgrib
Other names
dicyclomine + simethiconedicyclomine hydrochloride + simethiconedicycloverine hydrochloride + simethicone
02

Targets

Bradykinin B2 receptorH (Histamine receptors)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM5 (M5)

Beyond the preview

Go deeper on dicycloverine + simethicone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dicycloverine + simethicone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call